drugset / Trial / NCT07007325
Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)
NaSingle-groupOpen-labelDiagnostic
Summary
\[68Ga\]Ga-PentixaFor PET-CT will be performed in patients with Small cell lung cancer (SCLC) to confirm the targeting of CXCR4 by \[68Ga\]Ga-PentixaFor
Timeline
- Start
- 2026-09-30
- Primary completion
- 2028-09-30
- Completion
- 2030-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-Pentixafor | Peptide | 50 ug | Intravenous |
| Subject | 68Ga-Pentixafor | Peptide | 150 mbq | Intravenous |